BIOTECH CATALYST AI SCANNER — August WK2

Six of this week's ten featured names were in last week's report. That is not the scanner being lazy — it is what an August calendar looks like when a dozen companies all guided to "mid-2026" and the quarter is running out of days. Karyopharm holds #1 for a second week. Silence, Tenax, Longeveron and ArriVent all return. Ultragenyx and EyePoint climb off the watchlist and into the top ten as their dates come inside three weeks. The list is concentrated because the catalysts are.

The tightest window belongs to Ultragenyx: a PDUFA on August 23 for DTX401, followed by a second one on September 19 for UX111. Capricor's decision lands the day before, August 22, three weeks after an advisory committee voted 9–3 that its evidence did not establish effectiveness. The ESC Congress in Munich absorbs the cardiovascular names — Tenax presents Phase 3 LEVEL on August 29, Arrowhead the 12-month plozasiran detail on the 30th. Everything else stamped "Aug 2026 (Est.)" is a company-guided window our screen resolved to a month-end placeholder, not a date anyone has published. Two of them — ArriVent and Pyxis — are guiding to windows that have already slipped once.

A hard note on the data, because this week produced the worst single error we have caught. Our screen ranked Longeveron at #4 on a thesis the FDA has already rejected. In May the agency told the company that right ventricular ejection fraction is not sufficient to demonstrate efficacy in ELPIS II, and it no longer considers that trial pivotal. Our feed swallowed the company's "constructive Type C meeting" headline and scored the name as though the regulatory path were intact — the second time this specific press release has fooled it. The entry below is written as a correction. Read it before you read its rank.

One housekeeping note: as flagged in late July, this weekly newsletter winds down at the end of August. Three issues remain, this one included. Deep-dive pieces continue after that.

What We're Tracking:

Trading Below Gross Cash: KPTI ($48M cap / $91M cash — and see the debt note in its entry, which changes the conclusion), CAPR ($237M cap / $236M cash, roughly at cash)
Corrected This Week: LGVN (FDA de-pivoted ELPIS II — screen missed it), EYPT (screen labelled a pivotal Phase 3 as "Phase 2"), TENX and PYXS (nonsense runway fields — 1.3 and 0.4 months against real balances of $118M and ~$91M post-financing)
Post-Setback, Still Listed: KPTI (endometrial Phase 3 miss Jul 30), CAPR (AdCom 9–3 against Jul 29)
Deeply Oversold (RSI < 20): CAPR (10), KPTI (15)
Overbought Into the Print (RSI > 75): REGN (84), PYXS (82), LGVN (78)
Already Read Out — Detail Only, Not a Binary: ARWR (SHASTA-3/-4 hit on July 22; Aug 30 is the full dataset)
Multi-Catalyst (90 days): RARE, ARWR, IONS, SION

FEATURED

#1. KPTI — Karyopharm Therapeutics Inc.

THE CATALYST
Event: Selinexor (XPORT-MF-034, SENTRY) — sNDA submission seeking accelerated approval in JAK-inhibitor-naïve myelofibrosis
Date: Aug 2026 (Est.)
FDA Status: FTD
BSI: 8.81/10

On July 30 Karyopharm published two things in the same hour: its Phase 3 endometrial cancer trial had missed on progression-free survival, and the FDA had told it in writing that spleen response looks acceptable as the basis for a myelofibrosis filing. The market priced the first and largely ignored the second. The company sells XPOVIO (selinexor) commercially in multiple myeloma, is cutting planned endometrial spend, and has no partner on the myelofibrosis program. Q2 results are not yet out, so every balance-sheet figure here is a March 31 number.

A second week, and a second correction on the same field. Our screen tagged this "Negative EV" and "Deep Value" because $91M of cash sits above a $48M market cap. Arithmetically true; as an investment conclusion, wrong. The Q1 10-Q shows $397.1M of total liabilities against $131.4M of total assets — a stockholders' deficit of $265.6M — plus a senior secured term loan, 9% convertible notes due 2028 and 2029, a deferred royalty obligation, and an explicit going-concern warning. Net of debt the enterprise value is firmly positive. Anyone reading "trading below cash" as "downside is protected" has the sign backwards.

📈 The Setup: Myelofibrosis — a bone-marrow cancer that scars the marrow and swells the spleen — belongs to Incyte's ruxolitinib (Jakafi) in the front line, with fedratinib, pacritinib and momelotinib splitting narrower subgroups. Selinexor comes at it from a different angle: it blocks XPO1, the export protein tumour cells use to shuttle tumour-suppressor proteins out of the nucleus where they can do their job. In Phase 3 SENTRY (N=353, randomised 2:1), adding it to ruxolitinib roughly doubled the share of patients hitting SVR35 — a 35%-or-greater reduction in spleen volume at week 24 — against ruxolitinib alone, with a supportive early survival signal and reductions in mutant allele burden. The co-primary symptom score was missed. What changed on July 30 is regulatory, not clinical: the FDA gave written feedback that SVR35 appears to qualify as a reasonably likely surrogate endpoint for survival. This month's event is a filing, with Priority Review to be requested. The decision is a 2027 problem.

✅ The Edge: Written FDA agreement that SVR35 can carry an accelerated approval is the rarest asset a company this size can hold — it converts the surrogate-endpoint debate from an open question into a settled one before the application is even submitted. No JAK combination has ever cleared frontline myelofibrosis.
⚠️ The Risk: Agreement on an endpoint is not agreement on a filing. Priority Review must still be granted, the missed symptom-score co-primary gives reviewers something to hold onto, and a company carrying a going-concern flag and 2028 convertible maturities has almost no capacity to fund a delay or a confirmatory demand.

#2. SLN — Silence Therapeutics Plc

THE CATALYST
Event: Divesiran (SLN124, SANRECO) — Phase 2 topline data in polycythemia vera
Date: Aug 2026 (Est.)
FDA Status: FTD, ODD
BSI: 7.88/10

Divesiran is the asset Silence did not partner away. Years of value creation here ran through other people's programs — the AstraZeneca siRNA collaboration across cardiovascular, renal, metabolic and respiratory targets is still live, and Hansoh opted out of certain programs in 2025 — which makes a wholly-owned readout the company controls end to end unusual for this balance sheet. The parent is UK-domiciled and Nasdaq-listed. The stock is up 31% in three weeks into the print.

On the runway field: we show $70.1M, which is the March 31 figure and is real. The "into 2028" guidance attached to it in our feed traces back to a 2025 statement made when the cash balance was materially larger. We could not reconcile the two, and Q2 numbers are not out. Treat the runway as unverified rather than comfortable.

📈 The Setup: Polycythemia vera is a blood cancer of red-cell overproduction, and front-line management still means physically draining blood — therapeutic phlebotomy — propped up by hydroxyurea or ropeginterferon (Besremi), with ruxolitinib for the hydroxyurea-intolerant. Divesiran cuts off the raw material instead. It is a GalNAc-conjugated siRNA (a small RNA that switches off one specific gene, chemically tagged so the liver takes it up) aimed at TMPRSS6; silencing it raises hepcidin, the hormone that rations how much iron reaches the marrow. Starve the iron, throttle the production line. Phase 1 (n=21) held mean haematocrit at or below 45% across every dose with phlebotomies essentially eliminated, and the June EHA follow-up showed the effect outlasting the final dose. The Phase 2 is 48 patients, fully enrolled since October, testing six-week and twelve-week dosing. This is a genuine efficacy topline, not an update.

✅ The Edge: Protagonist and Takeda's rusfertide works the same hepcidin axis and needs weekly injections; its own FDA decision lands this quarter. The Q12W arm tests a four-times-a-year interval nobody else is positioned to offer in a disease where the practical enemy is adherence to a schedule.
⚠️ The Risk: Forty-eight patients, an open question on how much baseline cytoreductive therapy varies between arms, and a primary endpoint — haematocrit under 45% without phlebotomy across weeks 18–36 — that needs durability, not just depth. Phase 1 was small and single-arm; separation from placebo is the thing that has not been shown.

#3. TENX — Tenax Therapeutics Inc.

THE CATALYST
Event: TNX-103 (oral levosimendan, LEVEL) — Phase 3 topline data in pulmonary hypertension with preserved-ejection-fraction heart failure
Date: Aug 29, 2026
BSI: 7.21/10

Tenax funded itself to its own Phase 3 readout on warrant exercises rather than a discounted equity round — an unusual outcome for a company that was a micro-cap eighteen months ago. The focus is cardiovascular and pulmonary disease; the only material outside relationship is an amended supply and licence agreement with Orion for levosimendan. A CFO and a chief commercial officer were added this year, which is what a company does when it thinks it may have something to sell.

Our screen printed a runway of 1.3 months for this name. That figure is garbage — the real balance is roughly $118M, funded through Q2 2028, helped by $13.4M of warrant exercises in Q2. The snapshot above is corrected. Share count also varies by source (26.5M to 37.4M); treat the market cap as approximate.

📈 The Setup: Pulmonary hypertension in heart failure with preserved ejection fraction — stiff left ventricle, back-pressure into the lungs — has no approved therapy anywhere in the world. Treatment is diuretics and off-label PDE5 inhibitors. TNX-103 is oral levosimendan, an inodilator (it sensitises heart muscle to calcium and opens KATP channels, improving contraction and relaxing vessels without driving up the heart's oxygen demand), and the oral formulation is the whole point: intravenous levosimendan is an inpatient drug, this one is chronic outpatient therapy. The open-label HELP Phase 2 crossover (n=37) produced significant six-minute-walk gains and lower pulmonary capillary wedge pressure. LEVEL enrolled over 230 patients and a blinded sample-size re-estimation last December left it powered above 90% to detect a 25-metre walk-distance improvement. Late-breaker slot at ESC on the 29th. Fully binary, no partial credit.

✅ The Edge: A first registrational win in a disease with zero approved drugs, from a company that reached the finish line without a dilutive raise. Piper Sandler's price target move from $20 to $50 gives a sense of what the sell side thinks a positive print is worth.
⚠️ The Risk: Six-minute walk distance as a sole primary endpoint has no regulatory precedent in this exact population, and heart-failure exercise trials have a long history of placebo responses eating modest effects. There is no breakthrough designation here to smooth the path, and a twelve-week endpoint may not answer the durability question the FDA asks next.

#4. LGVN — Longeveron Inc. — ⚠️ RANK CORRECTED

THE CATALYST
Event: Laromestrocel (lomecel-B, ELPIS II) — Phase 2b topline data in hypoplastic left heart syndrome
Date: Aug 2026 (Est.)
FDA Status: FTD, ODD
BSI: 7.06/10 — see correction; we do not stand behind this rank

The correction first, because everything else depends on it. Our screen ranked this name #4 and described ELPIS II as a pivotal trial with FDA-aligned endpoints. That is wrong. At a Type C meeting disclosed in May, the FDA told Longeveron that the trial's primary endpoint — right ventricular ejection fraction — is not sufficient to demonstrate efficacy, and the agency no longer considers ELPIS II a pivotal study. It said it would revisit the program once results exist. Our feed read the company's "constructive Type C meeting" headline, scored the regulatory path as intact, and its fact-check layer passed the name clean. This is the second time this particular release has beaten our verification. A positive August readout is no longer a filing event; it is an argument for a meeting.

With that established: Longeveron develops allogeneic mesenchymal stem-cell therapies for rare paediatric and ageing-related conditions. A $15M first tranche of a $30M private placement closed in March, funding the company past this readout, and it has moved to an asset-light model looking for licensing partners across four programs.

📈 The Setup: Hypoplastic left heart syndrome is a birth defect in which the left side of the heart never forms properly. The fix is three staged open-heart operations — Norwood, Glenn, Fontan — leaving the right ventricle doing the work of two, with high rates of failure and transplant. No drug exists. Laromestrocel is a donor-derived, off-the-shelf mesenchymal stem-cell therapy injected into the heart muscle during the Glenn procedure, acting through pro-vascular, anti-inflammatory and tissue-repair signalling rather than by replacing tissue. ELPIS I (n=10 infants) showed 100% transplant-free survival at five years. ELPIS II randomised 40 patients across roughly twelve centres against surgery alone, and an independent monitoring committee reviewed the unblinded data in May and cleared it to finish unchanged. What it cannot do, on the FDA's own account, is support an approval on the endpoint it was built around. The stock is up 13% into the print with an RSI of 78.

✅ The Edge: An outside committee has already seen every patient's unblinded data and let the trial run — a read no public investor gets — in an indication where no competitor has a cell or regenerative therapy in late-stage development. Fast Track and orphan status are in hand and survive the endpoint dispute.
⚠️ The Risk: The regulator has said in advance that the primary endpoint does not prove efficacy. Even a clean win reopens a negotiation rather than closing one, and this company holds roughly $16M against a Q4 2026 runway — it has to finance that negotiation from a $24M market cap.

#5. PYXS — Pyxis Oncology Inc.

THE CATALYST
Event: Micvotabart pelidotin (MICVO, PYX-201) — Phase 1 monotherapy data update in 2L+ recurrent/metastatic head and neck cancer
Date: Aug 2026 (Est.) — company guidance is "mid-2026," most recently referenced as Fall; the August date is our screen's placeholder
FDA Status: FTD, ODD
BSI: 6.89/10

The June 30 financing is the reason this name is investable at all right now. Pyxis raised up to $114M — roughly $50M upfront from BVF Partners with the balance in warrants — pushing runway into Q2 2027 and clearing a cash cliff that would otherwise have sat directly under the readout. The company builds antibody-drug conjugates for hard-to-treat solid tumours; the lead asset traces to a 2021 worldwide licensing deal with Pfizer. An interim CEO has been running it since early this year.

Our screen showed a runway of 0.4 months, a leftover of the pre-financing cash figure. Corrected above.

📈 The Setup: Second-line recurrent/metastatic head and neck squamous cell carcinoma is a graveyard: patients have already progressed through platinum chemotherapy and a PD-1 inhibitor, and what is left works poorly. MICVO is an antibody-drug conjugate — a targeting antibody wired to a cell-killing payload — pointed at extradomain-B fibronectin, a protein the tumour lays down in its own surrounding matrix rather than on the cancer cell itself. That address is unusual, and it lets the drug attack density, blood supply and the cells at once. December 2025 Phase 1 data showed a 46% confirmed response rate and 92% disease control as monotherapy at 5.4 mg/kg, and 71% with pembrolizumab (Keytruda) in a smaller combination cohort. The update coming is a dose-cap analysis on the monotherapy expansion — how safety and efficacy hold when exposure is capped by weight. Combination data is a Q4 event. RSI 82 and +40% in three weeks means the good version of this print is partly in the price.

✅ The Edge: A 46% response rate in patients who have failed both platinum and PD-1 sits well above what single agents have historically produced in that line, and Fast Track is already granted for exactly that population.
⚠️ The Risk: These are small early cohorts with no mature progression-free or overall survival data, and the entire point of the coming update is a dosing change made after the fact. Response rates measured before and after a dose cap are not the same number, and the market is priced for the first one.

#6. AVBP — ArriVent BioPharma Inc.

THE CATALYST
Event: Firmonertinib (FURVENT) — Phase 3 topline data in first-line EGFR exon 20 insertion non-small cell lung cancer
Date: Aug 2026 (Est.) — guidance has moved from "early 2026" to "mid-2026" and remains unreported
FDA Status: BTD
BSI: 6.68/10

ArriVent's entire thesis rests on an in-licensing decision: ex-Greater China rights to firmonertinib, taken from Shanghai Allist in 2021. The company develops EGFR-targeted agents for lung cancer and runs a clinical collaboration with InnoCare on SHP2 inhibitor combinations. A July 2025 public offering and an active ATM facility, topped up with a $250M supplement in May, mean the readout is not a financing event. Note the drug's name has settled as firmonertinib; our feed still carries the older "furmonertinib" spelling.

📈 The Setup: EGFR exon 20 insertions are a lung-cancer subtype that classical EGFR inhibitors barely touch, and the first-line standard is amivantamab — an injected bispecific antibody — plus carboplatin and pemetrexed chemotherapy. Firmonertinib is an oral third-generation EGFR tyrosine kinase inhibitor built to hit exon 20 insertions and cross into the brain, where this cancer frequently spreads. In the Phase 1b FAVOUR study, treatment-naïve patients at 240 mg produced a 78.6% confirmed response rate (n=28) with median duration of 15.2 months, against PAPILLON's 73% and 11.4-month progression-free survival for amivantamab-chemo. FURVENT randomised 398 patients across two firmonertinib doses versus chemotherapy alone, with progression-free survival by blinded central review as the primary endpoint. The comparator is the catch, and it is worth sitting with: this trial is powered against chemotherapy, not against the regimen doctors actually use.

✅ The Edge: Breakthrough Therapy designation and a brain-penetrant oral pill in a disease where the approved first-line option is an intravenous bispecific plus chemotherapy every three weeks. In exon 20, roughly 40% of patients develop brain metastases — CNS response is not a secondary detail here.
⚠️ The Risk: Beating platinum chemotherapy is a lower bar than beating amivantamab-chemo, and reviewers and payers will both make that comparison whether or not the trial did. Two timeline slips also mean the readout is now overdue against the company's own guidance, and nobody outside knows why.

#7. RARE — Ultragenyx Pharmaceutical Inc.

THE CATALYST
Event: DTX401 (pariglasgene brogedenevec) — PDUFA regulatory decision in glycogen storage disease type Ia
Date: Aug 23, 2026
Additional catalysts: 1 more within 90 days — UX111 PDUFA, September 19, 2026
BSI: 6.20/10

Two FDA decisions in four weeks, on two different gene therapies, at a company that spent this year cutting costs to be ready for them. Ultragenyx develops therapies for rare and ultra-rare genetic disease and has a commercial base including the Crysvita collaboration. A 2026 restructuring reduced headcount and expense ahead of potential launches. The FDA has said it does not anticipate an advisory committee for DTX401.

A note for readers of our July issues: we previously attributed a Complete Response Letter to DTX401 in error. That CRL belonged to UX111, a separate Ultragenyx program — the Sanfilippo syndrome therapy that was resubmitted and now carries the September 19 date. DTX401's review has been clean. This week's data carries no such contamination.

📈 The Setup: In glycogen storage disease type Ia the liver cannot release stored glucose, so patients — many of them children — survive by eating raw cornstarch around the clock, including waking through the night, to avoid hypoglycaemia. There is no drug; the treatment is the diet. DTX401 is an AAV8 gene therapy (a modified virus used as a one-time delivery vehicle) carrying a working copy of the G6PC gene to liver cells in a single infusion. In the randomised Phase 3 GlucoGene study (n=44), treated patients cut daily cornstarch intake by a mean 41.3% at week 48 versus 10.3% on placebo (p<0.0001), with 68% of them achieving at least a 30% reduction against 13% of controls, and week-96 data showed deeper reductions with glucose control maintained. Beam's BEAM-301 is attacking the same disease by base editing, but it is years behind. The stock comes in oversold, down 23% on the month.

✅ The Edge: The trial measured the actual burden of the disease — how much cornstarch a patient must eat — and beat placebo on it with a p-value under 0.0001, in an indication where the only alternative is dietary management. No competitor has a filing.
⚠️ The Risk: Gene therapy reviews turn on manufacturing and durability as often as efficacy, and 44 patients with a 96-week cutoff is a thin base for a one-time, irreversible treatment. Priority Review buys speed, not leniency on chemistry and controls — and a CRL here would land three weeks before the second decision.

#8. STRO — Sutro Biopharma Inc.

THE CATALYST
Event: STRO-004 — Phase 1 first-in-human initial data in refractory metastatic solid tumours
Date: Aug 2026 (Est.)
BSI: 6.07/10

Sutro reverse-split 1-for-10 in December to hold its Nasdaq listing, then raised equity in February — and the share count has roughly doubled since. The company builds antibody-drug conjugates on a cell-free protein synthesis platform, which lets it place payloads at precise sites rather than at random. An Astellas partnership generates revenue; Merck and Ipsen deals sit in the history. Preclinical data across the pipeline was presented at AACR in April. Q2 results came out on August 6.

📈 The Setup: Tissue factor is a protein that shows up on the surface of many solid tumours, and exactly one drug exploits it — Pfizer and Genmab's Tivdak (tisotumab vedotin), approved only in recurrent cervical cancer and carrying a microtubule-disrupting payload. STRO-004 goes after the same target with a different weapon: exatecan, a topoisomerase-1 inhibitor, loaded eight molecules to an antibody at defined positions rather than scattered. The claim is that precise, high-density loading gives better tumour exposure and stability than conventional conjugation allows. Preclinical models showed activity above benchmark ADCs. What arrives this month is the first human evidence — an open-label dose escalation in refractory patients, reporting safety, pharmacokinetics and whatever early activity has appeared since the first cohort dosed in December. This is not a readout that proves anything. It is a readout that can disprove things.

✅ The Edge: The only next-generation tissue-factor ADC in the clinic that Sutro owns outright, on a platform whose whole selling point — exact payload placement — is the variable that determines whether a potent topoisomerase payload lands on tumour or on healthy tissue.
⚠️ The Risk: Topoisomerase-1 payloads carry real dose-limiting toxicity, and a first-in-human escalation in heterogeneous refractory tumours with variable target expression may generate too few evaluable patients to say anything. Tivdak already owns the one indication where tissue factor is proven; the burden is on Sutro to show a reason to look past it.

#9. EYPT — EyePoint Inc.

THE CATALYST
Event: DURAVYU (EYP-1901, LUGANO) — Phase 3 topline data in wet age-related macular degeneration
Date: Aug 2026 (Est.)
BSI: 6.07/10

Correction to our own screen: it classified this catalyst as Phase 2. LUGANO is a pivotal Phase 3 trial, confirmed in the company's August 5 quarterly release, which also put topline in August and LUCIA in Q4. The label understates the event.

EyePoint enrolled two large Phase 3 wet AMD trials in seven months and now has both reading out inside six months of each other. The company develops sustained-delivery treatments for retinal disease, principally wet AMD and diabetic macular oedema, and licensed Greater China rights for EYP-1901 to Betta Pharmaceuticals. Cash of $180M at June 30 funds operations into Q4 2027, past the whole readout sequence.

📈 The Setup: Wet AMD is treated by injecting an anti-VEGF drug into the eye — aflibercept (Eylea) every eight weeks after loading — and the treatment works. The problem is the schedule: patients miss visits, real-world vision outcomes drift below trial results, and the burden falls on elderly people who need someone to drive them. DURAVYU is a bioerodible insert carrying vorolanib, a tyrosine kinase inhibitor that blocks VEGF receptors from inside the cell rather than mopping up VEGF outside it, released steadily over roughly six months. Phase 2 DAVIO-2 (n=161, previously treated patients) hit statistical non-inferiority to aflibercept q8W on vision at both doses, with treatment burden down 80–89% and over 80% of eyes needing no supplemental injection at six months. LUGANO is the confirmatory version at 56 weeks, aflibercept-controlled and double-masked. Ocular Therapeutix's axitinib implant is running the same race one trial behind.

✅ The Edge: Two fully enrolled Phase 3 trials covering both treatment-naïve and previously treated patients, and three consecutive positive safety recommendations from the independent monitoring committee — depth of coverage no other sustained-release program in wet AMD currently has.
⚠️ The Risk: Non-inferiority on vision is unforgiving: if the TKI arm needs more rescue injections than modelled, the durability claim and the efficacy claim collapse together. Sustained-delivery candidates in this disease have repeatedly matched convenience and failed to match anti-VEGF potency.

#10. TYRA — Tyra Biosciences Inc.

THE CATALYST
Event: Dabogratinib (TYRA-300, SURF302) — Phase 2 initial three-month complete response data in FGFR3-altered low-grade intermediate-risk non-muscle-invasive bladder cancer
Date: Aug 2026 (Est.)
BSI: 6.04/10

Tyra is running a "3x3" strategy — three Phase 2 programs across oncology and achondroplasia — off a balance sheet that reaches into the second half of 2028. The company designs precision medicines against FGFR biology; the lead asset, TYRA-300, has been renamed dabogratinib. No partnerships are disclosed, which is deliberate: it is funded well enough not to need one. An EVP of clinical development was hired this year specifically for the skeletal dysplasia indications.

📈 The Setup: Low-grade intermediate-risk non-muscle-invasive bladder cancer is managed by repeatedly cutting tumours out under anaesthesia. It recurs; you go back. There is no targeted oral option, and the approved FGFR drug — erdafitinib — is a pan-FGFR inhibitor cleared for advanced disease, where hyperphosphataemia and stomatitis from hitting FGFR1, 2 and 4 are tolerated because the alternative is worse. Dabogratinib is engineered to hit FGFR3 and spare the rest, which is what makes an oral drug plausible in a low-grade, long-horizon setting where patients are not sick enough to accept that toxicity. SURF302 is open-label, randomising up to 90 patients between 50 mg and 60 mg daily, with three-month complete response rate as the primary endpoint. What reports this month is the first CR data from both cohorts — over 20 patients had enrolled as of Q1. Early, small, unblinded, and the first real efficacy signal the program has produced in this indication.

✅ The Edge: The only oral agent in clinical development for FGFR3-altered intermediate-risk NMIBC, in a setting where the competition is a surgical procedure rather than a drug. Selectivity is the entire product — it is what converts an advanced-disease molecule into an early-disease one.
⚠️ The Risk: Open-label complete response rates in a small cohort, assessed by the investigators running the study, are the softest kind of efficacy data. There is no randomised control here and no durability yet, so a strong headline number tells you the drug does something, not that it beats going back to the operating room.

WATCHLIST

#11. CAPR — Capricor Therapeutics Inc. [Rare Disease / Cell Therapy]

Price: $4.09 | Cap: $237M | Cash: ~$236M | RSI: 10 | Momentum: -81.0%
Deramiocel (CAP-1002, HOPE-3) — PDUFA regulatory decision in Duchenne muscular dystrophy (Aug 22, 2026)
ODD
BSI: 6.02/10

The Intel: On July 29 the FDA's cell and gene therapy advisory committee voted 9–3 that the evidence did not establish effectiveness, citing missing data, analytic sensitivity and heterogeneous cardiac outcomes. The vote is non-binding and the decision is due August 22, but Piper Sandler expects a second Complete Response Letter. Deramiocel delivers allogeneic cardiosphere-derived cells whose secreted vesicles damp inflammation and fibrosis in the heart — a different bet from the gene-replacement therapies that dominate DMD. The stock trades at roughly its cash balance, which is the market pricing the program near zero.

#12. BEAM — Beam Therapeutics Inc. [Genetic Medicine]

Price: $27.48 | Cap: $2.84B | Cash: ~$1.12B | RSI: 55 | Momentum: -15.9%
BEAM-302 — Phase 1/2 late-breaking data in severe alpha-1 antitrypsin deficiency (Sep 8, 2026)
RMAT
BSI: 5.99/10

The Intel: Our feed described this as newly cleared for first-in-human trials — that is stale by more than a year. BEAM-302 has dosed patients, has RMAT designation, and Beam dosed the first patient in a global pivotal cohort during Q2. The updated Phase 1/2 data lands as a late-breaker at the European Respiratory Society Congress in Barcelona, September 5–9. The approach is base editing: a single A-to-G correction of the PiZ mutation in SERPINA1, made in the liver via lipid nanoparticle, which should simultaneously cut the toxic misfolded protein and restore the functional one. Vertex's VX-864 and the broader small-molecule corrector field have not solved both halves of this disease. With $1.1B in cash, the readout is about the data, not the runway.

#13. SION — Sionna Therapeutics Inc. [Cystic Fibrosis]

Price: $51.04 | Cap: $2.31B | Cash: ~$201M | RSI: 63 | Momentum: +12.7%
SION-451 + SION-109 — Phase 1 topline data in healthy volunteers (Aug 2026 (Est.))
BSI: 5.89/10

The Intel: A healthy-volunteer Phase 1 reading out safety and drug exposure — useful, not pivotal, and priced as though it matters more than that at a $2.3B valuation on $201M of cash. SION-451 is a corrector, helping the defective CFTR protein fold properly; SION-109 is a potentiator, opening the channel once it reaches the cell surface. The obstacle is not scientific novelty but Vertex, whose Trikafta and Alyftrek franchise already treats the large majority of patients well. Sionna's argument is that its NBD1-stabilising approach reaches what Vertex leaves behind; nothing in this readout will test that.

#14. VALN — Valneva SE [Vaccines]

Price: $5.30 | Cap: $503M | Cash: ~$110M | RSI: 71 | Momentum: +5.0%
S4V2 (CHIM study) — Phase 2b challenge-study data in Shigella (Aug 2026 (Est.))
FTD
BSI: 5.85/10

The Intel: Our feed's summary claimed the latest challenge data confirmed efficacy. No results have been released — that claim is unsupported, and the runway field of zero months is a bug on a company with marketed vaccine revenue. S4V2 is a tetravalent bioconjugate vaccine covering four Shigella serotypes, partnered with LimmaTech, being tested in a controlled human infection model: roughly 120 volunteers vaccinated, then deliberately exposed to Shigella sonnei 53G a month later, with infection rates compared against placebo. There is no licensed Shigella vaccine anywhere. Valneva is French-domiciled and dual-listed, and takes over all further development if both this and the infant study read out positive.

#15. NGNE — Neurogene Inc. [Neurology / Gene Therapy]

Price: $35.69 | Cap: $682M | Cash: ~$330M | RSI: 41 | Momentum: -9.9%
NGN-401 (Embolden) — Phase 1/2 interim data in Rett syndrome (Aug 2026 (Est.))
BTD, RMAT
BSI: 5.84/10

The Intel: Our feed said the trial recently dosed its first patient; the same record shows dosing completed in June with 25 participants treated. The former is stale. NGN-401 delivers MECP2 via AAV9 with a self-regulating element — the central problem in Rett gene therapy is that too much MECP2 is as toxic as too little, which is what sank earlier attempts and what Taysha's TSHA-102 is also engineering around. Breakthrough and RMAT designations are in hand. The mid-2026 update is interim colour; registrational topline is guided to 2H 2027, so this is a data point, not a decision.

#16. PTGX — Protagonist Therapeutics Inc. [Hematology]

Price: $145.87 | Cap: $9.44B | Cash: ~$880M | RSI: 65 | Momentum: +11.0%
Rusfertide — PDUFA regulatory decision in polycythemia vera (Q3 2026)
BSI: 5.80/10

The Intel: Our screen printed "Aug 31, 2026" for this date. The FDA has not published a day — the accepted NDA carries a Q3 2026 action date, and the company has guided to August. Read the date as a quarter, not a deadline. Rusfertide is a hepcidin mimetic, injected weekly, that restricts iron availability to choke off excess red-cell production, and the Phase 3 VERIFY trial hit its primary and key secondary endpoints. Priority Review, Breakthrough, Orphan and Fast Track are all in hand. Takeda partners it. The name matters this week for a second reason: an approval would put the first hepcidin drug on the market within days of Silence reading out the siRNA version of the same idea (#2 above).

#17. REGN — Regeneron Pharmaceuticals Inc. [Large Cap / Rare Disease]

Price: $784.36 | Cap: $80.75B | Cash: ~$8.32B | RSI: 84 | Momentum: +18.0%
Garetosmab (OPTIMA) — PDUFA regulatory decision in fibrodysplasia ossificans progressiva (Aug 2026 target action date)
BSI: 5.64/10

The Intel: Same date caveat as PTGX — the BLA was accepted in February with a target action date in August 2026, not the month-end date our screen displays. Garetosmab blocks activin A, the protein Regeneron's own scientists identified as the driver of heterotopic ossification — the process that turns soft tissue into bone in FOP — and the Phase 3 OPTIMA trial met its primary endpoint with a reported 94% reduction in new lesions. Ipsen's palovarotene (Sohonos) is the only approved option and carries growth-plate warnings limiting paediatric use. For an $81B company this is a rounding error financially; the stock's RSI of 84 reflects other things entirely.

#18. ARWR — Arrowhead Pharmaceuticals Inc. [Cardiometabolic / RNAi]

Price: $87.65 | Cap: $12.38B | Cash: ~$1.47B | RSI: 73 | Momentum: +14.7%
Plozasiran (SHASTA-3/-4) — Phase 3 full 12-month results in severe hypertriglyceridemia (Aug 30, 2026)
BSI: 5.51/10

The Intel: This is not a binary. Topline already landed on July 22: both Phase 3 trials hit the primary triglyceride endpoint and every prespecified secondary, including a statistically significant reduction in acute pancreatitis. August 30 is the HOT LINE late-breaker at ESC in Munich delivering the full 12-month dataset — detail, subgroups and the pancreatitis curves, which is what determines the label conversation rather than whether there is one. Plozasiran is an siRNA silencing APOC3, dosed infrequently by subcutaneous injection. Ionis's Tryngolza is the competitor to watch on commercial positioning.

#19. IONS — Ionis Pharmaceuticals Inc. [Cardiometabolic / Antisense]

Price: $56.56 | Cap: $9.40B | Cash: ~$2.31B | RSI: 62 | Momentum: -2.9%
ION775 — Phase 1 results presented at ESC (Aug 2026)
BSI: 5.48/10

The Intel: A Phase 1 conference presentation at a company this size is a pipeline footnote, and our score reflects that. ION775 uses antisense oligonucleotides to suppress apolipoprotein C-III, the protein that blocks triglyceride clearance — the same target Arrowhead's plozasiran silences by a different mechanism, and the same target as Ionis's own marketed Tryngolza. The interesting question is whether ION775 is positioned to extend that franchise or defend it; a healthy-subject Phase 1 will not answer it. Ionis carries two further catalysts inside 90 days.

#20. CABA — Cabaletta Bio Inc. [Autoimmune / Cell Therapy]

Price: $2.79 | Cap: $455M | Cash: ~$205M | RSI: 53 | Momentum: -6.2%
Resecabtagene autoleucel (rese-cel, RESET-MG) — Phase 1/2 interim data in generalized myasthenia gravis (Aug 2026 (Est.))
BSI: 5.45/10

The Intel: Rese-cel is a fully human CD19-directed CAR-T that wipes out B cells to reset an autoimmune system, chasing durable drug-free remission from a single infusion — a very different proposition from the FcRn blockers and complement inhibitors (Vyvgart, Ultomiris, Rystiggo) that now dominate myasthenia gravis and must be dosed indefinitely. Data was presented at AAN in April; this is an incremental update. The obstacle is not mechanism but arithmetic: lymphodepleting chemotherapy and an autologous manufacturing slot is a heavy price in a disease where approved biologics already work reasonably well for most patients.

About This Scanner

This weekly report identifies biotech catalyst opportunities using quantitative screening combined with fundamental analysis.

What the Score Means: The BSI Score (0-10) reflects overall opportunity quality based on technical setup and fundamental characteristics. Higher scores indicate more favorable setups; lower scores indicate elevated uncertainty. This is NOT a prediction of catalyst outcomes or stock direction.

Data Sources: Financial data from market feeds and regulatory filings; prices reflect the August 7 close. Catalyst dates are estimates based on company guidance and subject to change — entries marked "(Est.)" resolve to a month-end placeholder in our feed and should be read as windows, not dates.

Manual Corrections Applied This Week: LGVN (FDA endpoint rejection and loss of pivotal status omitted by the automated fact-check), EYPT (trial phase misclassified), TENX and PYXS (invalid runway fields), KPTI (cash-above-market-cap flag corrected for debt and going-concern status; cash figure is as of March 31), SLN (runway guidance unverifiable against current cash), PTGX and REGN (month-end placeholder shown in place of an unpublished FDA action date), BEAM and NGNE (stale trial-status descriptions), VALN (unsupported efficacy claim and invalid runway field), AVBP (drug name spelling; timeline has slipped twice).

Important: This report is for informational and educational purposes only. It does not constitute investment, financial, or medical advice. Conduct your own due diligence before making investment decisions.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.3 | Generated: 2026-08-09T21:31:46